Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

26.21 +0.41 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences Inc

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential. 
Via MarketBeat
Topics Fraud Lawsuit
Exposures Criminal Legal
How Is The Market Feeling About Cassava Sciences?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
Via Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
Via Benzinga
Exposures Fossil Fuels
Cassava Sciences Unusual Options Activity
Via Benzinga
Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Market Whales and Their Recent Bets on SAVA Options
Via Benzinga
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
What's Going On With Cassava Sciences Today?
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher Monday. Here's what you need to know. 
Via Benzinga
(SAVA) - Analyzing Cassava Sciences's Short Interest
Via Benzinga
What's Going On With Cassava Sciences Shares Today?
Cassava Sciences is set to report its second-quarter earnings on Aug. 13, with an anticipated loss of 40 cents per share, according to Benzinga Pro. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Cassava Sciences Stock Dived by Almost 11% Today
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. 
Via The Motley Fool
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, misleading investors with false claims of cognitive improvement and selective... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Cassava Sciences News: Why Is SAVA Stock Trending Today?
Cassava Sciences stock is down on Tuesday even as investors take note of SAVA shares alongside a couple of pieces of news. 
Via InvestorPlace
Cassava Sciences Shares Are Trading Higher Today: What You Need To Know
Cassava Sciences, Inc. (NASDAQ: SAVA) saw its stock price soar by 15.5% to $27.13, an increase of $3.64, amid rising short interest and an anticipated conference call to discuss recent developments. 
Via Benzinga
Get Your Money Out of These 3 Healthcare Stocks ASAP
Many companies in the healthcare sector have great outlooks but these healthcare stocks to sell are facing very tough challenges 
Via InvestorPlace
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. 
Via Benzinga
Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
SmartRent (SMRT) Stock Plunges 21% as CEO Steps Down
SmartRent stock is falling on Tuesday as SMRT investors react to the resignation of the company's CEO and suspension of its 2024 outlook. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.